Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia

Vascular Health and Risk Management

Volumn 3, Issue 5, 2007, Pages 655-664

  Poon, Man Chiu ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Bleeding; Glanzmann's thrombasthenia; GPIIb IIIa; Platelet transfusion; Recombinant human activated factor VII (rFVIIa); Surgery

Indexed keywords

ANTIFIBRINOLYTIC AGENT; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTIBODY; HEMOSTATIC AGENT; HLA ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANTIBODY PRODUCTION; ANTICOAGULATION; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLEEDING; BOLUS INJECTION; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GLANZMANN DISEASE; HEART MUSCLE ISCHEMIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MONOTHERAPY; MUCOSAL BLEEDING; NONHUMAN; OPTIMAL DRUG DOSE; PHARYNX HEMORRHAGE; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; THROMBOSIS; TOOTH EXTRACTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; FACTOR VIIA; FIBRINOLYSIS; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS; THROMBASTHENIA;

EID: 36148957054     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Abshire T, Kenet G. 2004. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost, 2:899-909.
2. Aledort LM. 2004. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost, 2:1700-08.
3. Almeida AM, Khair K, Hann I, et al. 2003. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol, 121:477-81.
4. Bell JA, Savidge GF. 2003. Glanzmann's thrombasthenia proposed optimal management during surgery and delivery. Clin Appl Thromb Hemost, 9:167-70.
5. Berrettini M, Mariani G, Schiavoni M, et al. 2001. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica, 86:640-5.
6. Caglar K, Cetinkaya A, Aytac S, et al. 2003. Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr Hematol Oncol, 20:435-8.
7. Chuansumrit A, Sangkapreecha C, Hathirat P. 1999. Successful epistaxis control in a patient with Glanzmann thrombasthema by increased bolus injection dose of recombinant factor VIIa. Thromb Haemost, 82:1779.
8. Chuansumrit A, Suwannuraks M, Sri-Udomporn N, et al. 2003. Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia. Blood Coagul Fibrinolysis, 14:187-90.
9. Coppola A, Tufano A, Cimino E, et al. 2004. Recombinant factor VIIa in a patient with Glanzmann's thrombasthenia undergoing gynecological surgery: open issues in light of successful treatment. Thromb Haemost, 92:1450-2.
10. d'Oiron R, Menart C, Trzeciak MC, et al. 2000. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost, 83:644-7.
11. Dargaud Y, Bordet JC, Trzeciak MC, et al. 2006. A case of Glanzmann's thrombasthenia successfully treated with recombinant factor VIIa during a surgical procedure: observations on the monitoring and the mechanism of action of this drug. Haematologica, 91(6 Suppl):17-20.
12. Devecioglu O, Unuvar A, Anak S, et al. 2003. Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions. Turk J Pediatr, 45:64-6.
13. Diness V, Bregengaard C, Erhardtsen E, et al. 1992. Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model. Thromb Res, 67:233-41.
14. Dodd RY, Notari EP, Strainer SL. 2002. Current prevalence and incidence of infectious disease markets and estimated window-period risk in the American Red Cross blood donor population. Transfusion, 42:975-9.
15. Fressinaud E, Sigaud-Fiks M, Le Boterff C, et al. 1998. Use of recombinant factor VIIa (NovoSeven®) for dental extraction in a patient affected by platelet-type (pseudo-) von Willebrand disease. (Abstract) Haemophilia, 4:299.
16. George JN, Caen JP, Nurden AT. 1990. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood, 75:1383-95.
17. Hoffman M, Monroe DM III, Roberts HR. 1998. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis, 9 Suppl 1:S61-5.
18. Inagaki M, Mori T, Tsunematsu Y, et al. 2006. Use of recombinant activated factor VII to control bleeding in a young child with qualitative platelet disorder: a case report. Blood Coagul Fibrinolysis, 17:317-22.
19. Ito K, Yoshida H, Hatoyama H, et al. 1991. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple anti-platelet antibodies. Vox Sang, 61:40-6.
20. Jacobs MR, Palavecino E, Yomtovian R. 2001. Don't bug me: the problem of bacterial contamination of blood components - challenges and solutions. Transfusion, 41:1331-4.
21. Jurlander B, Thim L, Klausen NK, et al. 2001. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost, 27:373-84.
22. Kale A, Bayhan G, Yalinkaya A, et al. 2004. The use of recombinant factor VIIa in a primigravida with Glanzmann's thrombasthenia during delivery. J Perinat Med, 32:456-8.
23. Kaleelrahman M, Minford A, Parapia LA. 2004. Use of recombinant factor VIIa in inherited platelet disorders. Br J Haematol, 125:95-6.
24. Kenet G, Lubetskyb A, Luboshitz J, et al. 2003. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost, 1:450-5.
25. Langendonck L, Appel IM. 2005. Modification of biological parameters after treatment with recombinant factor VIIa in a patient with thrombocytopathy due to storage pool disease. Pediatr Blood Cancer, 44:676-8.
26. Lindley CM, Sawyer WT, Macik BG, et al. 1994. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther, 55:638-48.
27. Lisman T, Adelmeijer J, Heijnen F, et al. 2004. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood, 103:1720-7.
28. Lisman T, Moschatsis S, Adelmeijer J, et al. 2003. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood, 101:1864-70.
29. Lombardo VT, Sottilotta G. 2006. Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanzmann's thrombasthenia. Clin Appl Thromb Hemost, 12:115-16.
30. Lusher JM. 1998. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl, 63:7-10.
31. Lusher JM. 2000. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis, 11 Suppl 1:S45-9.
32. Martin I, Kriaa F, Proulle V, et al. 2002. Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthema and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol, 119:991-7.
33. Mayer SA, Brun NC, Begtrup K, et al. 2005. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med, 352:777-85.
34. McGregor L, Hanss M, Sayegh A, et al. 1989. Aggregation to thrombin and collagen of platelets from a Glanzmann thrombasthenic patient lacking glycoproteins IIb and IIIa. Thromb Haemost, 62:962-7.
35. Monroe DM, Hoffman M, Oliver JA, et al. 1997. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol, 99:542-7.
36. Monte S, Lyons G. 2002. Peripartum management of a patient with Glanzmann's thrombasthenia using Thrombelastograph. Br J Anaesth, 88:734-8.
37. Morrissey JH, Mutch NJ. 2006. Tissue factor structure and function. Hemostasis and Thrombosis. In Colman RE, Marder VJ, Clowes AW, George JN, Goldhaber SZ (ed). Basic Principles and Clinical Practice. 5th ed. Philadelphia. Lippincott Williams & Wilkins. p.91-106.
38. Musso R, Cultrera D, Russo M, et al. 1999. Recombinant activated factor VII as haemostatic agent in Glanzmann's thrombasthenia (Abstract). Thromb Haemost, 82 (Suppl):621.
39. Niewiarowski S, Levy-Toledano S, Caen JP. 1981. Platelet interaction with polymerizing fibrin in Glanzmann's thrombasthenia. Thromb Res, 23:457-63.
40. Nurden AT. 1999. Inherited abnormalities of platelets. Thromb Haemost, 82:468-80.
41. O'Connell KA, Wood JJ, Wise RP, et al. 2006. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA, 295:293-8.
42. Osdoit S, Rosa J-P. 2001. Polymeric fibrin interacts with platelets independently from integrin αIIbβ3 (Abstract). Blood, 98:518a.
43. Ozelo MC, Svirin P, Larina L. 2005. Use of recombinant factor VIIa in the management of severe bleeding episodes in patients with Bernard-Soulier syndrome. Ann Hematol, 84:816-22.
44. Peerschke EI, Zucker MB, Grant RA, et al. 1980. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood, 55:841-7.
45. Peters M, Heijboer H. 1998. Treatment of a patient with Bernard-Soulier, syndrome and recurrent nosebleeds with recombinant factor VIIa [letter]. Thromb Haemost, 80:352.
46. Phillips DR, Charo IF, Parise LV, et al. 1988. The platelet membrane glycoprotein IIb-IIIa complex. Blood, 71:831-43.
47. Poon M-C. 2006. Factor VIIa. In Michelson AA (ed). Platelets.2nd ed. Boston. Elsevier Science. p 1251-61.
48. Poon M-C, d'Oiron R, von Depka M, et al. 2004. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost, 2:1096-103.
49. Poon M-C, Demers C, Jobin F, et al. 1999. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood, 94:3951-3.
50. Poon M-C, Zotz R, DiMinno G, et al. 2006. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol, 43:S33-6.
51. Pozo Pozo AI, Jimenez-Yuste V, Villar A, et al. 2002. Successful thyroidectomy in a patient with Hermansky-Pudlak syndrome treated with recombinant activated factor VII and platelet concentrates. Blood Coagul Fibrinolysis, 13:551-3.
52. Reverter JC, Beguin S, Kessels H, et al. 1996. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest, 98:863-74.
53. Robinson KL, Savoia H, Street AM. 2000. Thrombotic complications in two patients receiving NovoSeven® (Abstract). Haemophilia, 6:349.
54. Sallah S, Isaksen M, Seremetis S, et al. 2005. Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity - a rebuttal. J Thromb Haemost, 3:820-2.
55. Santagostino E, Gringeri A, Mannucci PM. 1999. Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. Br J Haematol, 104:22-6.
56. Tengborn L, Petruson B. 1996. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa [letter]. Thromb Haemost, 75:981-2.
57. Turecek PL, Richter G, Muchitsch EM, et al. 1997. Thrombogenicity of recombinant factor VIIa and recombinant soluble tissue factor in an in vivo rabbit model. (Abstract) Thromb Haemost, 78 (Suppl):222.
58. Uzunlar HI, Eroglu A, Senel AC, et al. 2004. A patient with Glanzmann's thrombasthenia for emergent abdominal surgery. Anesth Analg, 99:1258-60.
59. van Buuren HR, Wielenga JJ. 2002. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia. Dig Dis Sci, 47:2134-6.
60. Villar A, Aronis S, Morfini M, et al. 2004/Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia, 10:352-9.
61. Yilmaz BT, Alioglu B, Ozyurek E, et al. 2005. Successful use of recombinant factor VIIa (NovoSeven) during cardiac surgery in a pediatric patient with Glanzmann thrombasthenia. Pediatr Cardiol, 26:843-5.